Konruns(603590) 中银国际·2025-04-08 02:45Investment Rating - The report maintains a "Buy" rating for the company, with a market price of RMB 27.21 and a sector rating of "Outperform" [1]. Core Views - The company has successfully completed the first patient enrollment in the Phase II clinical trial of its self-developed innovative drug KC1036 for treating advanced Ewing sarcoma in adolescents aged 12 and above, indicating positive long-term development prospects [3][7]. - The potential market for KC1036 is significant, with multiple indications entering clinical trials, including esophageal cancer, which has a large patient population in China [7]. - The company is undergoing a marketing transformation aimed at enhancing sales capabilities, which is expected to strengthen the sales of existing products and support the future sales of KC1036 [7]. - The earnings forecast has been adjusted due to goodwill impairment from the acquisition of Tailin Pharmaceutical and the impact of marketing reforms, with EPS projections for 2024-2026 set at RMB 0.32, 1.12, and 1.34 respectively [7]. Financial Summary - The company's main revenue is projected to grow from RMB 867 million in 2022 to RMB 1,209 million by 2026, with a CAGR of 12.9% [6]. - EBITDA is expected to increase significantly from RMB 154 million in 2022 to RMB 316 million in 2026 [6]. - The net profit attributable to the parent company is forecasted to rise from RMB 101 million in 2022 to RMB 213 million in 2026, reflecting a substantial growth rate of 19.5% in 2026 [6]. - The company’s PE ratio is projected to decrease from 85.6 in 2024 to 20.4 in 2026, indicating improved valuation over time [6].